- Headache, in a person affected by 1. Migraine, and with the characteristics of this headache type, fulfilling criterion C
- Calcitonin gene-related peptide (CGRP) has been administered
- Evidence of causation demonstrated by both of the following:
- headache has developed within 2-12 hours after administration of CGRP
- headache has resolved within 72 hours after administration of CGRP has ceased
- Not better accounted for by another ICHD-3 diagnosis1.
Phenomenologically, 220.127.116.11 Delayed CGRP-induced headache resembles migraine, but is regarded as secondary, attributed to the drug. The patient should be coded both for the appropriate type or subtype of 1. Migraine and 18.104.22.168 Delayed CGRP-induced headache.
While 22.214.171.124 Delayed CGRP-induced headache occurs only in a person affected by 1. Migraine and phenomenologically resembles this headache type, it is presumed that it is mechanistically distinct.